Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1401Other hematologic neoplasm 431Myeloid 34Plasma cell 29Sarcoma 27Dermatologic 15CNS 12Classical hematology 9Tumor-Agnostic 4Thoracic 4Breast 4Head & Neck 3Genitourinary 3Other solid neoplasm 2Gynecologic 2Gastrointestinal 2Other neoplasm 1Other 1

Conditions

Immune-related Adverse Events 1Advanced Solid Tumor 1

Interventions

Cisplatin 147pembrolizumab 129Carboplatin 125Injections 108Pemetrexed 99Paclitaxel 97Gemcitabine 85Irinotecan 75Cyclophosphamide 72Nivolumab 71Docetaxel 68Bevacizumab 59Oxaliplatin 50Fluorouracil 50Capecitabine 48atezolizumab 46Leucovorin 42Etoposide 42tislelizumab 40toripalimab 36fludarabine 32Drug Therapy 32Ipilimumab 30Topotecan 29durvalumab 28Vincristine 27Early Intervention, Educational 27Specimen Handling 26Radiotherapy 26Interviews as Topic 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Rituximab × Other solid neoplasm × Clear all
NCT04375228 2026-02-06

Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

Columbia University

Phase 2 Active not recruiting
8 enrolled
Other solid neoplasm

Immune-related Adverse Events

NCT05279300 2025-08-11

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

CStone Pharmaceuticals

Phase 1 Recruiting
480 enrolled
LymphoidOther solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡